Abatacept

• 

  Subject Areas on Research

  • A new look at blockade of T-cell costimulation: a therapeutic strategy for long-term maintenance immunosuppression. 
  • A pilot trial targeting the ICOS-ICOS-L pathway in nonhuman primate kidney transplantation. 
  • Alefacept promotes co-stimulation blockade based allograft survival in nonhuman primates. 
  • Anti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection. 
  • Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. 
  • Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function. 
  • Belatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapy. 
  • Belatacept and sirolimus prolong nonhuman primate renal allograft survival without a requirement for memory T cell depletion. 
  • Belatacept: is there BENEFIT for liver transplantation too? 
  • CD40 blockade combines with CTLA4Ig and sirolimus to produce mixed chimerism in an MHC-defined rhesus macaque transplant model. 
  • CD57(+) CD4 T Cells Underlie Belatacept-Resistant Allograft Rejection. 
  • CTLA-4-Mediated inhibition of early events of T cell proliferation. 
  • CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. 
  • CTLA4Ig prevents alloantibody formation following nonhuman primate islet transplantation using the CD40-specific antibody 3A8. 
  • CTLA4Ig: bridging the basic immunology with clinical application. 
  • Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection. 
  • Costimulator dependence of lymphokine secretion by naive and activated CD4+ T lymphocytes from TCR transgenic mice. 
  • Costimulatory molecules are active in the human xenoreactive T-cell response but not in natural killer-mediated cytotoxicity. 
  • Cutting edge: membrane lymphotoxin regulates CD8(+) T cell-mediated intestinal allograft rejection. 
  • Cytotoxic T lymphocyte antigen 4 (CTLA4) blockade accelerates the acute rejection of cardiac allografts in CD28-deficient mice: CTLA4 can function independently of CD28. 
  • De novo belatacept in clinical vascularized composite allotransplantation. 
  • High CTLA-4 expression on Th17 cells results in increased sensitivity to CTLA-4 coinhibition and resistance to belatacept. 
  • IFN-gamma dictates allograft fate via opposing effects on the graft and on recipient CD8 T cell responses. 
  • IL-7 receptor heterogeneity as a mechanism for repertoire change during postdepletional homeostatic proliferation and its relation to costimulation blockade-resistant rejection. 
  • Immune status assay (ISA): a noninvasive procedure for studying allograft rejection. 
  • In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. 
  • Inducing unresponsiveness by the use of anti-CD3 immunotoxin, CTLA4-Ig, and anti-CD40 ligand. 
  • Induction of peripheral T cell tolerance in vivo requires CTLA-4 engagement. 
  • LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function. 
  • Molecular basis of T cell inactivation by CTLA-4. 
  • Postdepletion Lymphocyte Reconstitution During Belatacept and Rapamycin Treatment in Kidney Transplant Recipients. 
  • Rapamycin Interferes With Postdepletion Regulatory T Cell Homeostasis and Enhances DSA Formation Corrected by CTLA4-Ig. 
  • Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors. 
  • Role of interleukin 12 and costimulators in T cell anergy in vivo. 
  • Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model. 
  • Selective costimulation modulation with abatacept: a look at quality-of-life outcomes in patients with rheumatoid arthritis. 
  • Selective targeting of human alloresponsive CD8+ effector memory T cells based on CD2 expression. 
  • Steroid-Responsive Acute Rejection Should Not Be the End Point for Immunosuppressive Trials. 
  • Subcutaneous Abatacept in Patients With Polyarticular-Course Juvenile Idiopathic Arthritis: Results From a Phase III Open-Label Study. 
  • Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. 
  • The allo- and viral-specific immunosuppressive effect of belatacept, but not tacrolimus, attenuates with progressive T cell maturation. 
  • Therapeutic effect of cytotoxic T lymphocyte antigen 4/immunoglobulin on a murine model of primary biliary cirrhosis.